Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status by Martina Broecker-Preuss et al.
Broecker-Preuss et al. BMC Cancer  (2015) 15:184 
DOI 10.1186/s12885-015-1186-0RESEARCH ARTICLE Open AccessSorafenib inhibits intracellular signaling pathways
and induces cell cycle arrest and cell death in
thyroid carcinoma cells irrespective of histological
origin or BRAF mutational status
Martina Broecker-Preuss1,4*, Stefan Müller2, Martin Britten1,5, Karl Worm3, Kurt Werner Schmid3, Klaus Mann1,6
and Dagmar Fuhrer1Abstract
Background: Patients with dedifferentiated or anaplastic thyroid carcinomas currently lack appropriate treatment
options. Kinase inhibitors are among the most promising new agents as alternative strategies. The BRAF- and
multi-kinase inhibitor, sorafenib, has already shown antitumor effects in thyroid carcinoma patients in a phase
III clinical trial. In this study we aim to better characterize molecular effects and efficacy of sorafenib against
thyroid carcinoma cells with various histological origins and different BRAF mutational status. Analysis of different
signaling pathways affected by sorafenib may contribute to assist a more specific therapy choice with fewer side
effects. Twelve thyroid carcinoma cell lines derived from anaplastic, follicular and papillary thyroid carcinomas
with wildtype or mutationally activated BRAF were treated with sorafenib. Growth inhibition, cell cycle arrest,
cell death induction and inhibition of intracellular signaling pathways were then comprehensively analyzed.
Methods: Cell viability was analyzed by MTT assay, and the cell cycle was assessed by flow cytometry after
propidium iodide staining. Cell death was assessed by lactate dehydrogenase liberation assays, caspase activity assays
and subG1 peak determinations. Inhibition of intracellular pathways was analyzed in dot blot and western blot analyses.
Results: Sorafenib inhibited proliferation of all thyroid carcinoma cell lines tested with IC50 values ranging between
1.85 and 4.2 μM. Cells derived from papillary carcinoma harboring the mutant BRAFV600E allele were slightly
more sensitive to sorafenib than those harboring wildtype BRAF. Cell cycle analyses and caspase assays
showed a sorafenib-dependent induction of apoptosis in all cell lines, whereas increased lactate dehydrogenase
release suggested cell membrane disruption. Sorafenib treatment caused a rapid inhibition of various MAP kinases in
addition to inhibiting AKT and receptor tyrosine kinases.
Conclusions: Sorafenib inhibited multiple intracellular signaling pathways in thyroid carcinoma cells, which resulted in
cell cycle arrest and the initiation of apoptosis. Sorafenib was effective against all thyroid carcinoma cell lines regardless
of their tumor subtype origin or BRAF status, confirming that sorafenib is therapeutically beneficial for patients with any
subtype of dedifferentiated thyroid cancer. Inhibition of single intracellular targets of sorafenib in thyroid carcinoma
cells may allow the development of more specific therapeutic intervention with less side effects.
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Thyroid carcinoma originating from thyroid follicular
cell is the most common endocrine malignancy [1,2].
About 90% of thyroid carcinomas are well differentiated,
while 10% or less are poorly differentiated or anaplastic
subtypes [2,3]. Of the differentiated carcinomas, 85 to
90% are papillary and 10 to 15% follicular subtypes. Most
differentiated carcinomas progress slowly, and patients
usually become disease-free after initial treatment with
thyroidectomy and radioiodine ablation. In contrast, 10 to
15% of patients initially diagnosed with differentiated car-
cinomas experience recurrent disease [1,4,5]. A reduction
in radioiodine uptake and storage accompanies tumor de-
differentiation. Dedifferentiated tumors are more aggres-
sive and lead to a worse patient outcome [3,5,6]. Tumors
initially categorized as poorly differentiated (PDTC) or an-
aplastic thyroid carcinomas (ATC) share these features
early on. Anaplastic (undifferentiated) thyroid carcinomas
are highly aggressive and lethal tumors that have com-
pletely lost the ability to take up iodine [7]. Beside their
aggressive growth particularly the loss of capacity to up-
take iodine makes both dedifferentiated and anaplastic
thyroid carcinomas difficult to treat, and confer the poor
patient prognosis. Moreover, chemotherapeutic treatment
proved to be largely ineffective against aggressive thyroid
carcinomas [8]. These inadequacies of current treatment
protocols for dedifferentiated and anaplastic thyroid car-
cinomas strongly emphasize the urgent need to establish
novel targeted treatment options.
A better understanding of the molecular alterations
driving thyroid tumorigenesis can drive development of
appropriate targeting agents for thyroid carcinoma. Mu-
tations in genes encoding the proteins of the mitogen
activated protein (MAP) kinase signaling cascade (RAS-
RAF-mitogen-activated protein kinase kinase (MEK)-
extracellular-signal regulated kinase (ERK)) frequently
occur in thyroid carcinomas [2,3]. About 50% of papil-
lary thyroid carcinomas (PTC) harbor activating muta-
tions in the BRAF gene (mostly BRAFV600E), an effector
of MEK that in turn activates the ERK1 and ERK2
mitogen-activated protein kinases (Review [9,10]). BRAF
mutations also occur in up to 13% of PDTCs and 35% of
ATCs [11], but in these subtypes are restricted to tumors
with a papillary component or supposed to be derived
from PTC [12]. The BRAFV600E mutation has been associ-
ated with advanced clinical stage, loss of iodine accumula-
tion and has an independent prognostic value for PTC
recurrence [13,14]. Mutations in the three RAS genes,
HRAS, KRAS and NRAS, have been described in all thy-
roid epithelial carcinoma subtypes (Review [3]). Besides
direct mutational activation of the RAS-RAF-MEK-ERK
signaling pathways, receptors with intrinsic tyrosine kin-
ase activity can also stimulate this cascade. Overexpres-
sion and autocrine activation of the epidermal growthfactor receptor (EGFR) in thyroid carcinomas contributes
to the activation of the RAS-MAP kinase cascade [15,16].
Expression of the platelet-derived growth factor receptors
(PDGFR) and their ligands in undifferentiated thyroid cells
[17,18] also activates this cascade. An aberrant activation
of the RAS-RAF-MEK-ERK signaling cascade, therefore,
is common in all thyroid carcinoma subtypes, and may
provide targets for appropriate molecular therapies.
Inappropriate activation of the MEK-ERK kinase cas-
cade leads to deregulated cell proliferation, dedifferenti-
ation and improved cell survival in a variety of tumor
cell types [19]. The importance of this pathway and its
frequent deregulation and mutational activation in can-
cers has led to development of small molecule inhibitors.
One of these inhibitors is sorafenib (Nexavar®, BAY43-
9006), which was originally designed to inhibit the ARAF,
BRAF and RAF1 kinases [20]. Sorafenib competitively
inhibits ATP binding to RAF catalytic domains, thus,
inhibiting kinase activity via stabilization of the conserved
kinase domain in the inactive configuration [21]. Sorafenib
was shown to potently inhibit RAF1 kinase, wildtype
BRAF and oncogenic BRAFV600E in vitro [22]. Moreover,
sorafenib directly blocks the autophosphorylation and ac-
tivation of several receptor tyrosine kinases, including
PDGFRB, fibroblast growth factor receptor 1 and vascular
endothelial growth factor receptors (VEGFRs) [20]. Soraf-
enib decreases ERK activation in human tumor cells, in-
hibits cell proliferation in vitro and inhibits growth of
human tumor xenografts in nude mice [20,23,24]. Sorafe-
nib has been shown to inhibit RAF activation, phosphoryl-
ation of members of the MEK-ERK kinase family and
proliferation of cell lines derived from PTC and ATC har-
boring an activating BRAF mutation [25]. These effects
were similar after BRAF knockdown using siRNA, sug-
gesting a central role for mutationally activated BRAF
[25]. Furthermore, Carlomago et al. [26] showed that so-
rafenib inhibits RET kinase and thus proliferation of papil-
lary and medullary thyroid carcinoma cells harboring an
oncogenic RET kinase. Sorafenib treatment inhibited pro-
liferation and improved survival of mice with ATC xeno-
grafts [27]. Taken together, these results demonstrate the
efficacy of sorafenib against various cell lines derived from
PTCs and ATCs. However, current published reports
include no data directly comparing cell lines with and
without BRAF mutations or describing the effects of
sorafenib in cell lines derived from follicular thyroid car-
cinomas (FTC).
Some clinical phase II trials and clinical studies in pa-
tients with metastatic differentiated thyroid carcinomas
have shown promising results for sorafenib [28-32]. The
majority of these studies detected no differences in treat-
ment efficacy between thyroid carcinoma subtypes, al-
though the low case numbers in these studies may have
hindered subgroup analysis. Positive effects were reported
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showed partial responses in 2 of 20 patients and stable dis-
ease in 5 of 20 patients [33]. A recently published phase
III multicenter, double-blind randomized and placebo-
controlled trial evaluating the efficacy of sorafenib in
thyroid cancer patients (DECISION study) [34,35] demon-
strated that sorafenib significantly improved progression-
free survival compared with placebo in patients with
progressive radioiodine-refractory differentiated thyroid
cancer independent of the clinical and genetic subgroup.
Overall, sorafenib has exhibited significant antitumor ac-
tivity and clinical benefits in patients with progressive and
advanced thyroid carcinoma and thus is a treatment op-
tion for patients with locally recurrent or metastatic, pro-
gressive, differentiated thyroid carcinoma refractory to
radioactive iodine treatment.
Since sorafenib as a multikinase inhibitor blocks vari-
ous intracellular signaling pathways, significant side ef-
fects have also been reported in clinical trials [36]. A
broader analysis of the signaling molecules affected by
sorafenib treatment in specific tumor cell types may thus
be useful to identify cell-specific key signaling molecules
for more directly targeted treatment approaches. No data
are currently available on the intracellular effects of soraf-
enib in thyroid carcinoma cells or potential differences in
sorafenib action in thyroid carcinoma cells of the papillary
(with or without the BRAF V600E mutation), follicular or
anaplastic subtypes. The aim of the present study was to
elucidate the effects of sorafenib treatment on prolifera-
tion, cell death induction and intracellular signaling path-
ways in various thyroid carcinoma cell lines.
Methods
Compounds and antibodies
Sorafenib (BAY 43–9006, Nexavar®) was provided by Bayer
Health Care (Wuppertal, Germany), stored in 10 mM ali-
quots in DMSO at −20°C and further diluted in the appro-
priate medium. Antibodies to detect both total protein and
activated phosphorylated forms of c-Jun N-terminal kinase
(JNK), AKT, p44/42 MAP kinase (ERK1/2) and p38 MAPK
were purchased from Cell Signaling Technology (Danvers,
MA, USA).
Cell lines and cell culture
Cell lines derived from the anaplastic, papillary and fol-
licular thyroid cancer subtypes were used in this study.
The SW1736 [37], HTh7 [38], HTh74 [39], HTh83 [40],
and C643 [17] cell lines were derived from ATC. BHT101
[41], B-CPAP [42], and TPC [43] cell lines were derived
from PTC. ML1 [44] and TT2609 [45] are FTC-derived
cell lines. The FTC133, FTC236 and FTC238 [46] cell
lines were derived from a single primary FTC, a lymph
node metastasis and a lung metastasis from the same pa-
tient, respectively. The HTh7, HTh74, HTh83, C643 andSW1736 cell lines were a gift from Prof. Heldin (Uppsala,
Sweden), and all other cell lines were purchased from
ATCC (Manassas, VA, USA), ECACC (Salisbury, UK) and
DSMZ (Braunschweig, Germany). Cell lines were main-
tained in their appropriate media supplemented with 10%
fetal bovine serum (FBS, Life Technologies, Paisley, PA,
USA) at 37°C at 5% CO2.
DNA extraction and mutation analysis
Genomic DNA was isolated from cell lines using the
QIAamp DNA kit (Qiagen, Hilden, Germany) according
to the manufacturer’s instructions. Primers used to amp-
lify exon 15 of the BRAF gene were described elsewhere
[47]. For PCR amplification, 5 μl of DNA solution con-
taining 200 ng DNA was used in a 50 μl reaction con-
taining 1xPCR buffer, 1.5 mM MgCl2, 1.5U HotMaster
Taq polymerase (Eppendorf, Hamburg, Germany) and
300 nM each of forward and reverse primers. Cycling
conditions were 40 cycles of 94°C for 20 sec, 55°C for
10 sec, 65°C for 35 sec. PCR products were analyzed on
3% agarose gels and purified using the QIA quick re-
moval kit (Qiagen). Sequencing was performed using
the ABI Prism BigDye Terminator Cycle sequencing kit
v1.1 on an ABI Prism 3100 Genetic Analyzer (Applied
Biosystems, Foster City, CA, USA). Sequences were com-
pared to the wildtype sequences using the Sequencher
software (Gene Codes, Ann Arbor, MI, USA).
Cell proliferation studies
For proliferation assays, 1 × 104 to 5 × 104 cells (cell line
dependent) were seeded into 96-well plates containing
the appropriate growth medium. Medium was replaced
after 24 hours with culture medium without FBS but
containing 0.1% bovine serum albumin (BSA) and the
indicated sorafenib concentrations was added. After
48 hours, viable cells were stained with the Cell Titer
Aqueous One Solution assay (Promega, Madison, WI,
USA), and optical density at 490 nm was measured using
an Emax microplate photometer (Molecular Devices,
Sunnyvale, CA, USA). Control values without sorafenib
treatment were performed as 22-fold determinations,
while all concentrations of sorafenib were tested in 8-
fold. Calculation of results and Student’s t-test were per-
formed using SoftMax pro software (Molecular Devices),
and IC50 values were calculated using Sigma Plot soft-
ware (Systat, San Jose, CA, USA).
Determination of lactate dehydrogenase release and
caspase 3/7 activity measurement
Release of lactate dehydrogenase (LDH) from cells with
damaged membranes was measured by the CytoTox-ONE
homogeneous membrane integrity assay (Promega). Activ-
ity of caspases 3 and 7 was measured by the Apo-ONE
homogeneous Caspase 3/7 assay (Promega). 1 × 104 to
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black, transparent-bottomed 96-well plates containing the
appropriate growth medium. Medium was removed after
24 h and 100 μl culture medium without FBS, but con-
taining 0.1% BSA and the denoted sorafenib concentra-
tion, was added to each well. After 14 or 24 hours, 50 μl
of medium from each well was transferred to a fresh black
96-well plate and equilibrated to 20°C. According to the
manufacturer’s instructions, 50 μl of CytoTox reagent was
added and reactions were incubated for 10 min in the
dark. After adding 25 μl of stop solution, fluorescence
was determined with excitation and emission wave-
lengths of 560 nm and 590 nm, respectively. Wells con-
taining no cells, as the zero setting, and fully lysed cells, as
the maximum LDH release control, were included in each
experiment. Caspase 3 and 7 activity in treated cells was
determined in the original stimulation plate by adding
50 μl of Apo-ONE reagent that contained a fluorometric
substrate in cell lysis and reagent buffer. After 60 min,
fluorescence was measured at 521 nm after excitation with
499 nm. All values were performed as 8-fold determina-
tions. Calculation of results and Student’s t-tests were per-
formed using SoftMax pro software (Molecular Devices).
Cell cycle analysis
Cells were plated at 1 × 105 to 5 × 105 cells/well in 6-
well plates in appropriate growth medium for cell cycle
analyses. Medium was replaced with medium without
FBS but containing 0.1% BSA and 3 μM sorafenib 24 h
later and cells were treated for the indicated times.
Treated cells were harvested and fixed in cold 70% etha-
nol. RNase A (60 μg/ml) and propidium iodide (25 μg/ml)
in PBS were added, and samples were incubated 20 mi-
nutes in the dark at room temperature. Samples were
measured on a FACS Calibur flow cytometer (Becton
Dickinson, San Jose, CA), and cell cycle stages were ana-
lyzed using the ModFit Software (Verity Software House,
Topsham, ME, USA).
Proteome Profiler™ array and western blot analysis
Proteome Profiler™ antibody arrays (R&D systems, Mineapolis,
MN, USA) and western blotting were used to assess in-
hibitory effects of sorafenib on intracellular signaling pro-
teins and receptor tyrosine kinases. Cells were plated in
10 cm culture dishes, and grown for 1–2 days to 85 to
90% confluency. Medium was removed and cells were
washed once and maintained in prewarmed HBSS buffer
(Life Technologies) for 20 minutes before adding 3 μM so-
rafenib. Treated cells were washed with ice-cold PBS, and
all further steps were performed on ice. Cells were lysed
in lysis buffer containing cOmplete protease inhibitor
and phosSTOP phosphatase inhibitor cocktails (Roche
Applied Science, Mannheim, Germany). Lysates were
clarified by centrifugation at 10,000 × g for 10 min at4°C, protein concentration determined by modified
Bradford assay (Bio-Rad Laboratories, Hercules, CA,
USA) and 500 μg of protein from each lysate were used in
dot blot analysis according to the manufacturer’s instruc-
tions. For western blotting, 30 μg of total protein was de-
natured by boiling for 5 minutes in SDS sample buffer,
then separated by SDS-PAGE and transferred to nitrocel-
lulose membranes (Bio-Rad Laboratories). After blocking
with 5% skim milk powder or 5% BSA in TBS, blots were
incubated with the appropriate primary antibody in TBS
buffer containing 0.1% Triton X-100 (TBS-T) overnight at
4°C. After washing, an appropriate secondary antibody
coupled to horseradish peroxidase in TBS-T was added.
Bound antigens on western and dot blots were detected
using the ECL Advance chemiluminescence detection kit
(GE Healthcare, Piscataway, NJ, USA). Signal intensity
was evaluated with a CCD camera system, and differences
were calculated with the Quantity One software (Bio-Rad
Laboratories).
Statistical analysis
Statistical analysis of treatment versus control groups
was performed by means of the unpaired Student’s t-test
using SPSS (IBM Inc, Armonk, NY, USA) or the other
software packages indicated above. P-values < 0.05 were
considered statistically significant.
Results
Sorafenib inhibited proliferation of cell lines derived from
all thyroid tumor subtypes irrespective of BRAF status
To assess whether sorafenib has a selective effect on pro-
liferation of cells with different histological and molecular
thyroid carcinoma backgrounds, we treated 12 cell lines
with different histological origins and BRAFV600E muta-
tional status for 48 h with a range of sorafenib concentra-
tions or vehicle and assessed proliferative activity. We first
assessed the mutational status of exon 15 of the BRAF
gene in all cell lines using PCR. The BHT101 and B-CPAP
papillary cell lines both harbored a heterozygous BRAFV600E
mutation. The anaplastic cell line, SW1736 also harbored
a heterozygous BRAFV600E mutation which is suggestive
that the anaplastic tumor has originated from a papillary
carcinoma (Table 1). Only wildtype BRAF alleles were de-
tected in the TPC1 papillary cell line, the C643, HTh7 and
HTh83 anaplastic cell lines and the FTC133, FTC236,
FTC238, ML1 and TT2609 follicular cell lines (Table 1).
Sorafenib treatment decreased the number of viable
cells in all 12 thyroid carcinoma cell lines analyzed, and
efficiency of sorafenib did not span a large range, since
IC50 values for all 12 cell lines were between 1.85 μM
and 4.2 μM (Table 1). The BHT101 and B-CPAP papil-
lary cell lines, which harbor the BRAFV600E mutation
had the lowest IC50 values (2.1 and 1.85 μM), while
SW1736 cells (anaplastic cell line with BRAFV600E
Table 1 Cell line characteristics, BRAFV600E mutational
status and viability after sorafenib treatment for











BHT101 Papillary Heterozygous 2.1 1.0
B-CPAP Papillary Heterozygous 1.85 1.0
TPC1 Papillary No 2.6 0.05
FTC133 Follicular No 2.9 1.0
FTC236 Follicular No 3.2 0.5
FTC238 Follicular No 4.2 0.01
ML1 Follicular No 2.95 2.0
TT2609 Follicular No 3.05 1.0
SW1736 Anaplastic Heterozygous 3.25 1.0
HTh83 Anaplastic No 3.95 2.0
C643 Anaplastic No 3.2 0.01
HTh7 Anaplastic No 3.1 2.0
sorafenib (µM)


















Figure 1 Sorafenib reduced the viability of thyroid carcinoma
cell lines of different histological derivation. Cells were cultured
with increasing concentrations of sorafenib or vehicle (DMSO)
control for 48 h, and viability was assessed by MTT assay. Values are
reported as percent of vehicle control ± standard deviation, and
represent mean values of eight determinations of one representative
experiment of three. IC50 values and the lowest concentration that
caused a significant loss of viability for all cell lines examined are
depicted in Table 1.
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which are derived from PTC but harbor no BRAFV600E
mutation, had an IC50 value in the lower range that was
slightly higher than those of the other 2 papillary cell
lines, which harbor BRAFV600E mutations. The follicular
cell lines, FTC133, FTC236, ML1 and TT2609, and the
C643 and HTh7 ATC cell lines also had midrange IC50
values (2.9-3.2 μM and 3.1-3.2 μM, respectively). HTh83
ATC cells and FTC238 FTC cells were most insensitive
to sorafenib, with IC50s of 3.95 and 4.2 μM, respectively.
While no dramatic differences were observed in the sen-
sitivity of cell lines from different histological origins or
with or without the BRAFV600E activating mutations to
sorafenib, some trends were observed. The three papil-
lary cell lines had the lowest overall IC50 values, and
the two papillary cell lines harboring the BRAFV600E
mutation (BHT101 and B-CPAP) were slightly more sensi-
tive than TPC1 cells. However, the only BRAFV600E muta-
tion harboring anaplastic cell line (SW1736) had an IC50
in midrange of the IC50s for all 4 anaplastic cell lines.
These results indicate that BRAF activation does not play
any role in undifferentiated carcinoma cells. Cell lines
from follicular carcinomas, with exception of the relatively
insensitive FTC238 cells, had midrange IC50 values sug-
gesting that sorafenib targets kinases other than BRAF in
these cells. Results for one representative cell line of all
histological origins with or without BRAFV600E mutation
(SW1736 cells (anaplastic with BRAFV600E mutation),
HTh7 (anaplastic without BRAFV600E mutation), BHT101
(papillary with BRAFV600E mutation) and ML1 (follicular
without BRAFV600E mutation) are depicted in Figure 1.
In addition to determination of IC50 values, for each
experiment we noted the lowest sorafenib concentrationthat significantly inhibited cell viability compared to un-
stimulated controls (Table 1). Interestingly, the lowest
effective sorafenib concentration was in a wide range in
all cell lines examined (0.05 to 2.0 μM; Table 1). It was
the lowest in FTC238 (follicular cell line), C643 (ana-
plastic) and TPC1 (papillary cell line without BRAFV600E
mutation) cells (0.01 μM and 0.05 μM sorafenib; Table 1).
HTh7 and HTh83 (both anaplastic cell line without
BRAFV600E mutation) and ML1 follicular cells were the
most insensitive cell lines with respect to the lowest ef-
fective concentration of sorafenib (2.0 μM; Table 1).
Taken together, sorafenib treatment effectively inhibited
viability of all twelve cell lines with different histological
and molecular thyroid tumor backgrounds, producing
IC50 values ranging from 1.85 to 4.2 μM. The presence
of the activating BRAFV600E mutation appeared to render
cell lines derived from the more differentiated papillary
tumors slightly more suseptible to sorafenib, while acti-
vated BRAF in SW1736 cells derived from anaplastic tu-
mors had no effect on sorafenib efficacy.
Sorafenib increased the proportion of cells in subG1 peak
and induced cell cycle arrest in thyroid carcinoma cells
To investigate the effects of sorafenib on cell cycle distri-
bution and on cell death-associated DNA fragmentation,
the 12 cell lines were analyzed flow cytometrically after
propidium iodide staining following sorafenib treatment.
The subG1 fraction increased markedly in all cell lines an-
alyzed after 24 h treatment with 3 μM sorafenib, indicating
that sorafenib induced cell death and DNA fragmentation
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subG1 peak was the highest in TPC1 papillary (72.4%)
and HTh83 anaplastic cells (74.4%). Increases were lowest
in the subG1 peaks of TT2609 (21.5%) and FTC133
(22.1%) follicular cells and HTh7 anaplastic cells (25.7%),
but were still significant. Cell lines derived from PTC ap-
peared most susceptible to cell death induction by sorafe-
nib, with the highest percentages of cells in subG1 after
treatment (60.2 to 72.4%). Sorafenib had the most variable
effect on anaplastic cell lines, increasing the subG1 frac-
tion in HTh7 cells by 25.7% and in HTh83 cells by 74.7%.
In follicular cell lines percentage of subG1 fraction varies
from 21.5% in TT2609 to 43.0% in FTC238 cells. Presence
of the activating BRAFV600E mutation appeared not to in-
fluence the ability of sorafenib to induce DNA fragmenta-
tion in cells of various histological origins. In the cells that
did not enter subG1, sorafenib appeared to have varying
effects on the cell cycle. Sorafenib treatment increased
the proportion of cells in G1 and decreased the propor-
tion of cells in S phase in all papillary cell lines (BHT101,
B-CPAP and TPC1) and in the SW1736 and HTh7 ana-
plastic cell lines (Figure 2 and Table 2). Sorafenib treat-
ment had the opposite effect on the C643 anaplastic cell
line and the FTC133, FTC236 and FTC238 follicular cell
lines, which responded by increasing numbers in S phase
and decreasing numbers in the G1 phase. Sorafenib
caused an increase in the proportion of ML1 follicular
cells and HTh83 anaplastic cells in the G2/M phase ac-
companied by fewer cells in S phase, while the cell cycle
distribution in TT2609 follicular cells was not significantly
altered.
Sorafenib induced cell death in thyroid carcinoma cells
To follow up on our detection of the decrease of viable
cells and the increase of cells in subG1 after sorafenib
treatment, we analyzed cell death in one cell line each
derived from the papillary and follicular and in two cellFigure 2 Cell cycle changes in C643 cells before and after incubation
conducted using FACS, and this figure shows the complete results for one
remaining living cells a decrease in G1 phase and in G2/M-phase and an in
lines examined are depicted in Table 2.lines derived from the anaplastic thyroid tumor sub-
types. We monitored release of LDH into the culture
medium, which results from the disruption of cell mem-
branes and release of LDH with other cytoplasmic com-
ponents. BHT101 papillary cells, ML1 follicular cells and
SW1736 and HTh7 anaplastic cells were treated for ei-
ther 14 h or 24 h with sorafenib before measuring LDH
in the culture medium. LDH was significantly elevated in
the culture medium from all four cell lines after sorafenib
treatment compared to controls treated with only DMSO
carrier concentrations (Figure 3a). The LDH levels re-
leased by SW1736 and ML1 cells after 24 h of treatment
were slightly higher than levels released by HTh7 and
BHT101 cells. Elevated LDH activities therefore reflected
cell membrane disruption after sorafenib treatment. To
assess whether cell death was due to apoptotic mecha-
nisms, we assessed activity of the caspases 3 and 7 after
sorafenib treatment. Caspase activities were significantly
elevated after both 14 h and 24 h of sorafenib treatment in
all four thyroid carcinoma cell lines (Figure 3b). Elevations
in caspase 3 and 7 activities were nearly the same after ei-
ther 14 h or 24 h of treatment in all four cell lines, sug-
gesting an early activation of the apoptotic machinery by
sorafenib. Overall, sorafenib not only decreased the num-
ber of viable cells and inhibited the cell cycle progression
of thyroid carcinoma cells from all histological derivations,
but caused apoptotic cell death with DNA fragmentation,
caspase activation, cell membrane disruption and LDH
release.
Sorafenib diminished MAP kinase and receptor tyrosine
kinase activation in thyroid carcinoma cells
To analyze which signaling pathways are targeted and
disrupted in thyroid carcinoma cells by sorafenib, we
assessed levels of phosphorylated members of the MAP
kinase family and of receptor tyrosine kinases after sorafe-
nib treatment for 10 minutes in BHT101, ML1, SW1736with 3 μM sorafenib for 24 h hours. Cell cycle analysis was
cell line as an example. Besides the increase in SubG1 peak, in the
crease in S-phase of cell cycle was observed. Values for the other cell
Table 2 Percentage of thyroid carcinoma cells determined by FACS analysis in each cell cycle phase following 24 h of
treatment with sorafenib or vehicle
Cell line Type Status %SubG1 %G1 %G2/M %S
BHT101 Papillary Unstimulated 4.5 ± 0.6 58.3 ± 3.9 17.7 ± 0.9 24.0 ± 1.3
Sorafenib 24 h 60.2 ± 6.4* 72.1 ± 5.8* 13.4 ± 0.7* 14.5 ± 0.9*
B-CPAP Papillary Unstimulated 6.8 ± 2.3 57.1 ± 2.7 14.0 ± 1.1 28.9 ± 1.4
Sorafenib 24 h 62.3 ± 7.3* 69.8 ± 4.6* 23.1 ± 1.2* 7.1 ± 0.4*
TPC1 Papillary Unstimulated 3.1 ± 0.4 48.1 ± 3.5 25.3 ± 1.6 26.6 ± 1.3
Sorafenib 24 h 72.4 ± 5.9* 57.6 ± 4.2* 27.6 ± 3.5 14.8 ± 0.8*
FTC133 Follicular Unstimulated 1.5 ± 0.3 57.0 ± 3.5 13.7 ± 0.8 29.3 ± 1.5
Sorafenib 24 h 22.1 ± 3.4* 46.9 ± 4.4* 8.7 ± 0.5* 44.4 ± 2.9*
FTC236 Follicular Unstimulated 1.2 ± 0.2 64.1 ± 5.0 12.1 ± 0.9 23.8 ± 1.1
Sorafenib 24 h 35.2 ± 3.7* 36.0 ± 3.1* 15.6 ± 1.0* 48.4 ± 3.7*
FTC238 Follicular Unstimulated 0.7 ± 0.1 46.1 ± 2.9 9.3 ± 0.6 44.6 ± 5.8
Sorafenib 24 h 43.0 ± 5.0* 24.2 ± 1.4* 11.0 ± 1.7 64.6 ± 6.6*
ML1 Follicular Unstimulated 1.0 ± 0.1 56.5 ± 3.2 18.1 ± 1.2 25.4 ± 1.3
Sorafenib 24 h 40.4 ± 3.2* 59.9 ± 2.7 25.5 ± 1.8* 14.4 ± 0.8*
TT2609 Follicular Unstimulated 1.6 ± 0.2 57.6 ± 4.6 11.5 ± 1.3 30.9 ± 1.8
Sorafenib 24 h 21.5 ± 3.0* 54.7 ± 6.0 13.1 ± 1.6 32.2 ± 3.1
SW1736 Anaplastic Unstimulated 2.2 ± 0.3 46.0 ± 2.9 10.1 ± 1.1 43.9 ± 2.7
Sorafenib 24 h 53.6 ± 3.9* 68.1 ± 5.5* 9.7 ± 0.7 22.2 ± 1.2*
C643 Anaplastic Unstimulated 1.0 ± 0.1 50.5 ± 3.7 15.1 ± 0.8 34.4 ± 2.8
Sorafenib 24 h 43.8 ± 4.0* 38.6 ± 2.6* 11.5 ± 0.5* 49.9 ± 3.5*
HTh7 Anaplastic Unstimulated 5.9 ± 0.8 52.2 ± 3.5 14.5 ± 0.8 33.3 ± 1.8
Sorafenib 24 h 25.7 ± 3.4* 76.9 ± 6.4* 1.2 ± 0.1* 21.9 ± 0.9*
HTh83 Anaplastic Unstimulated 5.6 ± 0.3 36.5 ± 2.6 24.3 ± 1.7 39.2 ± 2.0
Sorafenib 24 h 74.7 ± 5.7* 35.0 ± 5.2 34.5 ± 1.9* 30.5 ± 1.5*
Values for subG1 peaks represent the percentage of all cells measured, while values for G1-, G2/M- and S-phase are depicted for the remaining living cells. Values
are given as mean values ± standard deviation of 6-fold determinations. *indicates significant changes (p<0.05, Student’s t-test).
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several common tyrosine kinase receptors using commer-
cially available antibody arrays. Sorafenib inhibited the
phosphorylation of VEGFR1 (FLT1), VEGFR2 (KDR) and
PDGFRB in all four cell lines (Table 3). Sorafenib also
inhibited phosphorylation of PDGFRA, which is expressed
in the SW1736 and HTh7 anaplastic cells but not the
BHT101 or ML1 cell lines (Table 3). Phosphorylation of
VEGFR3 (FLT4) was significantly diminished in all cell
lines but ML1. Sorafenib did not affect receptors of the
EGFR family (EGFR, ERBB2, ERBB3 and ERBB4), the in-
sulin receptor or the insulin-like growth factor receptor
(IGF1R), which is in line with previous results of Wilhelm
and co-workers (Wilhelm et al., 2006; Table 3). We inves-
tigated phosphorylation of AKT1, AKT2 and AKT3 as
well as several MAP kinase family members, including
JNK, p44/42 MAP kinase (ERK1/2) and p38 MAP kinase
using dot blot analyses after sorafenib treatment of the
same four cell lines for 10 minutes. Sorafenib significantlyreduced phosphorylation of ERK1 in all four cell lines and
ERK2 only in the two anaplastic cell lines, SW1736 and
HTh7 (Table 4). Phosphorylation of the p38 alpha, −beta
and -gamma isoforms was reduced in all four cell lines,
while phosphorylation of the delta isoform of p38 MAP
kinase was only diminished in SW1736 cells after sorafe-
nib treatment (Table 4). Sorafenib significantly reduced
JNK2 phosphorylation in all four cell lines, but reduced
JNK1 and JNK3 phosphorylation only in HTh7 and ML1
cells, respectively. Phosphorylation of AKT1 and AKT2
was significantly reduced in all the four cell lines and
AKT3 only in HTh7 and BHT101 cells by sorafenib
(Table 4). Dot blot results were verified using western
blotting of whole-cell lysates from SW1736 and BHT101
cells treated 1, 5 and 10 minutes with sorafenib. Western
blots confirmed that sorafenib reduced the phosphoryl-
ation of ERK, p38 MAP kinase, JNK and AKT proteins
within 5 to 10 minutes, while total protein remained con-
stant (Figure 4). Taken together, sorafenib suppressed
Figure 3 Sorafenib induces cell death in thyroid carcinoma cell
lines. SW1736, HTh7, BHT101 and ML1 cells were incubated for 14 h
and 24 h with 3 μM sorafenib or vehicle (DMSO). LDH release
into the cell culture medium was measured using the Cytotox
assay (a), and increased caspase 3 and 7 activity was detected
using the ApoOne assay (b). Data represent mean values of
eight-fold determinations ± standard deviation, and are depicted
as percent of vehicle-treated control. *indicates significant increase
(p<0.05, Student’s t-test).
Table 3 Dot blot analysis of tyrosine receptor kinase
phosphorylation in SW1736, HTh7, BHT101 and ML1 cells
after short-term (10 min) treatment with 3 μM sorafenib
% of untreated control
Protein SW1736 HTh7 BHT101 ML1
p-VEGFR1 41.3 ± 7.2* 27.2 ± 11.5* 62.5 ± 7.4* 70.3 ± 4.6*
p-VEGFR2 30.3 ± 10.2* 45.7 ± 8.8* 60.7 ± 5.7* 75.6 ± 6.7*
p-VEGFR3 44.2 ± 7.2* 67.9 ± 8.9* 68.3 ± 10.4* 94.1 ± 7.1
p-PDGFRA 46.6 ± 6.0* 28.5 ± 11.1* n.e. n.e.
p-PDGFRB 67.0 ± 8.1* 57.3 ± 6.8* 67.2 ± 10.9* 64.2 ± 9.0*
p-EGFR 102.8 ± 7.8 107.4 ± 10.4 105.0 ± 7.3 93.0 ± 11.4
p-ERBB2 96.3 ± 6.9 91.8 ± 9.9 101.5 ± 11.8 101.9 ± 9.3
p-ERBB3 111.3 ± 8.8 108.7 ± 7.4 95.3 ± 10.8 96.2 ± 11.6
p-ERBB4 107.5 ± 11.0 110.3 ± 12.4 94.9 ± 10.71 102.6 ± 7.8
p-insulinR 103.9 ± 6.9 97.7 ± 10.3 96.6 ± 8.8 112.1 ± 12.0
p-IGF1R 112.6 ± 10.5 101.8 ± 9.9 95.9 ± 8.9 110.3 ± 10.3
VEGFR: vascular endothelial growth factor receptor, PDGFR: platelet-derived
growth factor receptor, EGFR: epidermal growth factor receptor, IGF1R: insulin-like
growth factor 1 receptor, n.e.: not expressed.
Values for the respective protein compared to the vehicle-treated control ±
standard deviation are depicted and represent 6-fold determinations. *indicates
significant decrease (p<0.05, Student’s t-test).
Table 4 Dot blot analysis of the activation of MAP kinase
family members in SW1736, HTh7, BHT101 and ML1 cells
after short-term treatment (10 min) with 3 μM sorafenib
% of untreated control
Protein SW1736 HTh7 BHT101 ML1
p-ERK1 54.2 ± 8.1* 67.1 ± 4.5* 45.4 ± 9.2* 82.0 ± 6.0*
p-ERK2 76.0 ± 5.4* 73.7 ± 3.7* 84.1 ± 5.7 88.1 ± 7.9
p-p38 alpha 38.9 ± 8.4* 44.4 ± 6.0* 32.2 ± 8.9* 61.3 ± 6.6*
p-p38 beta 68.6 ± 6.2* 80.7 ± 2.8* 75.9 ± 6.3* 76.7 ± 7.1*
p-p38 gamma 64.7 ± 5.9* 75.2 ± 5.4* 49.3 ± 5.7* 49.5 ± 8.3*
p-p38 delta 78.4 ± 5.0* 82.8 ± 8.8 83.6 ± 8.4 89.3 ± 6.9
p-JNK1 89.0 ± 7.7 79.1 ± 5.7* 86.7 ± 7.9 73.0 ± 9.8*
p-JNK2 61.2 ± 7.1* 75.1 ± 6.2* 77.5 ± 7.0* 63.2 ± 6.2*
p-JNK3 103.5 ± 7.7 86.3 ± 8.6 89.6 ± 5.4 69.2 ± 6.8*
p-AKT1 72.1 ± 5.9* 80.2 ± 5.8* 83.4 ± 6.3* 75.7 ± 5.5*
p-AKT2 74.7 ± 9.2* 80.0 ± 7.2* 81.9 ± 7.0* 77.4 ± 6.1*
p-AKT3 92.3 ± 8.3 77.6 ± 6.2* 81.5 ± 5.6* 86.6 ± 9.7
Abbreviations: ERK extracellular-signal regulated kinase, p38 p38 mitogen-activated
kinase, JNK c-jun N-terminal kinase, AKT AKT/protein kinase B.
Values for the respective protein compared to the vehicle-treated control ±
standard deviation are depicted and represent 6-fold determinations. *indicates
significant decrease (p<0.05, Student’s t-test).
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cells treated in vitro, including VEGFRs, PDGFRs as well as
various MAP kinase- and AKT-dependent pathways.
Discussion
Here we present a detailed analysis of kinase inhibition,
effects on the cell cycle and apoptosis induction by the
BRAF- and multikinase inhibitor, sorafenib, in thyroidcarcinoma cell lines of various histological subtypes with
and without activating BRAFV600E mutations. The effects
of sorafenib on various intracellular signaling molecules
were studied to evaluate more specific treatment options
in patients with dedifferentiated thyroid carcinomas pa-
tients. We assessed the BRAFV600E mutational status for all
12 cell lines used in this study. The activating BRAFV600E
Figure 4 Sorafenib suppressed phosphorylation of ERK, p38-MAP
kinase, JNK and AKT in SW1736 and BHT101 thyroid carcinoma
cells. Cells were treated with 3 μM sorafenib for 1, 5 and 10 minutes.
Whole-cell lysates were examined using western blot analysis.
Expression of total protein was used as control. Signal intensities
of phosphorylated proteins were corrected for signal intensities
of total proteins and expressed as percent of untreated control.
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cell lines (BHT101 and B-CPAP) and in one of the four
cell lines (SW1736) as previously detected and reported
[12,48]. The HTh7, C643 and HTh83 anaplastic cell lines,
the TPC papillary cell line and the FTC133, FTC236,
FTC238, ML1 and TT2609 follicular cell lines harbored
only wildtype alleles for BRAF. These findings fit well
with experimental and pathological evidence indicating an
involvement of BRAF mutation in the pathogenesis of
about 50% of PTCs and the progression of PTC to ATC,
but no occurrence of BRAF mutations in FTC [9,10,12,49].
Proliferation of all cell lines was inhibited by sorafenib
within the 48 h treatment period. To our knowledge,
ours is the first report about the inhibitory effects of so-
rafenib not only on cell lines derived from PTCs and
ATCs, but also from FTCs. It is in good agreement withrecent clinical findings in the phase III DECISION trial of
sorafenib in patients with iodine-refractory thyroid cancer,
where positive effects of sorafenib on progression-free sur-
vival was found in all clinical and genetic biomarker sub-
groups [35]. In contrast, Kloos et al. [29] reported better
clinical responses to sorafenib in patients with PTC than
in those with FTC (in patients with PTC partial response
in 15% and stable disease in approx. 65% of patients, in
patients with FTC no partial response and stable disease
in 80% of patients, in patients with ATC stable disease
in 25% of patients) [29]. IC50 values for sorafenib in the
various cell lines investigated in the present study ranged
from 1.85 μM to 4.2 μM, which correspond to the lower
range of achievable plasma levels. A daily dose of 400 mg
sorafenib administered orally or 2 doses of 200 mg per
day resulted in mean plasma levels of 20 μM in patients
during a phase I trial [50]. The two papillary cell lines
BCPAP and BHT101 with the BRAFV600E mutations had
the lowest IC50 values for sorafenib, while a slightly
higher IC50 value was calculated for the TPC1 papillary
cell line, which harbors no BRAFV600E mutation, but the
RET/PTC1 rearrangement [51]. Cell lines derived from
FTCs and ATCs responded similarly in this study, as evi-
denced by IC50 values within a relatively narrow range.
These IC50 values for FTC and ATC cell lines were
slightly higher than those for PTC cell lines, but still com-
parable to the lower range of plasma concentrations that
are achieved in patients [50]. Recently, Cohen et al. re-
ported on a synergistic effect of sorafenib treatment with
withaferin A in the B-CPAP and SW1736 thyroid carcin-
oma cell lines [52]. IC50 values for sorafenib treatment
alone were 6.3 μM (B-CPAP) and 7.6 μM (SW1736). Al-
though the IC50 values we report are somewhat lower,
with 1.85 μM for B-CPAP and 3.25 μM for SW1736, they
are in the same order of magnitude with BCPAP being the
more sensitive cell line. The IC50 values we report are
close to the IC50 values in the 1 μM-range reported by
Salvatore et al. for sorafenib treatment of the FRO, ARO,
KAT4 and NPA ATC cell lines harboring BRAFV600E
mutations [25]. IC50 values for thyroid carcinoma cell
lines are also very close to those reported in the literature
for hepatocellular carcinoma cell lines (4.5 and 6.3 μM)
[24] and melanoma cell lines (~5 μM) [53,54] treated with
sorafenib.
The lowest sorafenib concentration that led to a
significant antiproliferative effect in our study was the
lowest in three cell lines without BRAFV600E mutations:
In the fast growing C643 and FTC238 cells, significant
effects on cell number were achieved with 0.01 μM. In
papillary TPC1 cells significant effects were achieved with
0.05 μM sorafenib while in BHT101 and B-CPAP cells
significant inhibition was achieved with 1.0 μM as the lowest
concentration. The molecular reasons for these effects
are unclear, and may stem from the multikinase-inhibitor
Broecker-Preuss et al. BMC Cancer  (2015) 15:184 Page 10 of 13activity of sorafenib. It also points to positive effects that
may be achieved by sorafenib even in low concentrations
due to side effects during sorafenib treatment.
Sorafenib induced cell death in all 12 thyroid carcin-
oma cell lines investigated here, regardless of histological
derivation or the presence of the activating BRAFV600E
mutation. We detected increases in the percentage of
cells in subG1 for all cell lines, and different influences
on cell cycle progression depending on the cell line. So-
rafenib induced a larger proportion of cells of papillary
and anaplastic cell lines to enter subG1 than of follicular
cell lines, indicating that sorafenib has a different kind
of intracellular effect on DNA fragmentation in follicular
cell lines. Analysis of the proportion of the treated cul-
ture that did not enter subG1 revealed that G1 arrest
was induced in all PTC and two of four ATC cell lines,
while S phase arrest with G1 decrease was induced in
one ATC and three FTC cell lines. The TT2609 follicular
cell line showed no alteration in cell cycle phases of the
living proportion of the culture. These data concerning
the G1 arrest together with the occurrence of a subG1
peak are in agreement with literature data on the TPC1
papillary thyroid carcinoma cell line, the TT medullary
thyroid carcinoma cell line [26] and the ARO anaplastic
thyroid carcinoma cell line treated with sorafenib con-
centrations in a similar concentration range as we used
in vitro [25]. On the other hand, Liu et al. observed a de-
crease in the number of cells in G1 and an increase of
cells in S phase in HepG2 hepatocellular carcinoma cells
treated with sorafenib [24]. These results indicate that
sorafenib affects the cell cycle differently depending on
the cellular background. Since all papillary cell lines we
examined as well as the SW1736 anaplastic cell line har-
boring the activating BRAFV600E mutation and HTh7
cells arrested in G1 after sorafenib treatment, one may
speculate that inhibition of the overactivated RAF-MAP
kinase pathway in these cells contributes to the G1 ar-
rest while other, yet unidentified, molecular effects lead
to arrest in the S or G2/M phases in the other cell lines.
We further characterized the mechanism of cell death
in detail in four thyroid carcinoma cell lines. We chose
BHT101 as an example of a PTC cell line with a hetero-
zygous BRAFV600E mutation, ML1 as a FTC cell line,
SW1736 as an ATC cell line harboring the BRAFV600E
mutation and HTh7 as an ATC cell line with wildtype
BRAF. All four cell lines showed marked LDH release
into the medium after 14 and 24 hours of treatment,
confirming plasma membrane breakdown and release of
cytoplasmic contents. Apoptotic cell death was con-
firmed by the increased activity of caspases 3 and 7 in all
four cells lines. Interestingly, values for LDH release and
caspase activities were in the same magnitude in all four
cell lines. LDH release was slightly, but not significantly
higher in SW1736 and ML1 cells compared to BHT101and HTh7 cells. In contrast, caspase 3 and 7 activities
were slightly, but not significantly elevated in BRAFV600E
mutation-positive SW1736 and BHT101 cells compared
to HTh7 and ML1 cells. These results are in contrast to
recently reported results by Preto and coworkers [55],
who reported that sorafenib treatment only significantly
induced apoptosis in anaplastic thyroid cells harboring
a homozygous BRAF V600E mutation (8505C cell line),
but not in thyroid carcinoma cells with wildtype BRAF
(C643 and TPC1 cell lines). Preto et al. used the TUNEL
assay to quantify apoptosis, and since TUNEL detects
DNA fragments directly, it corresponds methodically to
quantification of the subG1 peaks in our study. Kim et al.
[27] on the other hand observed no correlation between
the inhibition of cell proliferation or apoptotic induction
(measured as subG1 peak) and the presence of the acti-
vating BRAFV600E mutation in five anaplastic thyroid
carcinoma cell lines treated with sorafenib [27] which is
in accordance with our results. Analysis of caspase activ-
ity, however, reflects other mechanisms of cellular death
than investigation of DNA fragmentation by subG1 peak
analysis and the TUNEL assay. Caspases are key effector
proteins in apoptosis that initiate systemic structural dis-
assembly in dying cells and have a multitude of intracellu-
lar substrates (Review [56]). Concerning the effects of the
BRAFV600E mutation to apoptosis resistance, Lee et al. re-
cently showed in the nontransformed PCCl3 rat thyroid
cells and in the cervical carcinoma cell line, HeLa, that
transfection with an inducible BRAFV600E construct medi-
ates resistance to mitochondrial-induced apoptosis follow-
ing sorafenib treatment [57]. Overall, the effect of
BRAFV600E mutation on apoptosis induction appears to be
different in various cellular contexts. In our experimental
setting, apoptosis induction and membrane disruption
after sorafenib treatment was not significantly influenced
by the histological origin of and BRAF mutational status
of thyroid carcinoma cells.
We also examined the of sorafenib on phosphorylation
of specific tyrosine kinase receptors in selected thyroid
carcinoma cell lines to better assess the impact of differ-
ing cellular backgrounds from histological derivation
and the presence of the activating BRAFV600E mutation.
Screening of receptor tyrosine kinase receptor activation
to identify the inhibitory mechanism of sorafenib exhib-
ited similar results in all four cell lines. Sorafenib inhib-
ited phosphorylation of VEGFRs and PDGFRs receptors,
but did not affect phosphorylation of insulin receptors,
IGF1R and the EGF family of receptors in thyroid car-
cinoma cells. These results fit well with results reported
for other cell types [22,58]. Sorafenib treatment in vivo
has been shown to also inhibit these tyrosine kinase re-
ceptors in endothelial cells and, thus, be capable of inhi-
biting tumor vascularization [20]. In vitro biochemical
assay showed that sorafenib directly inhibits the RAF1,
Broecker-Preuss et al. BMC Cancer  (2015) 15:184 Page 11 of 13BRAF and oncogenic BRAFV600E kinases, but has no sig-
nificant inhibitory effects on MEK, ERK, AKT and other
signaling pathways [22]. Complex crosstalk mechanisms
can occur between signaling pathways in the cell, how-
ever, that lead to stepwise activation of different path-
ways depending on the cellular context. The ERK kinase
inhibition we observed and that has been described by
others in thyroid carcinoma cells [24-26] can easily be
explained by inhibition of receptor tyrosine kinases or
the RAF1 or BRAF molecule in the RAF-MEK-ERK kin-
ase cascade [19]. We observed a more pronounced in-
hibition of ERK1 than ERK2 by sorafenib in thyroid
carcinoma cells. We can only speculate about the molecu-
lar mechanism behind this effect at this time. Differential
regulation of ERK1 and ERK2 was already described in
other systems (Review [59]). The diminished AKT phos-
phorylation we observed in thyroid carcinoma cells, beside
possible direct effects, may also be the result of receptor
tyrosine kinase inhibition by sorafenib and has recently
been described in prostate cancer cells [60]. Inhibition of
p38 MAP kinase by sorafenib has already been reported in
cell-free kinase assays [20]. An inhibition of p38 MAP kin-
ase and JNK by sorafenib comparable to that in our cells
was also reported in human hepatoma cell lines [61]. JNK
phosphorylation was also reported to be suppressed in
endothelial cells after sorafenib treatment [62].
Conclusions
In summary, our results demonstrate that the BRAF-
and multikinase inhibitor, sorafenib, exhibited various
inhibitory effects on intracellular signaling pathways in
thyroid carcinoma cells and caused cell death and cell
cycle arrest. Since sorafenib was effective against all thy-
roid carcinoma cell lines, independent of their histo-
logical derivation or the presence of an activating BRAF
mutation, these in vitro data are in accordance with data
collected so far from patients with various thyroid car-
cinoma subtypes treated with sorafenib in clinical trials.
Our data support the hypothesis that sorafenib may be
effective against dedifferentiated thyroid cancers of all
histological subtypes and regardless of their BRAF status.
The intracellular targets of sorafenib in thyroid carcin-
oma cells described in this study may allow the develop-
ment of more specific therapeutic intervention with less
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